Media Coverage

Although it is crucial to identify tick-borne diseases, including Lyme, early, many tests can be inaccurate or difficult to interpret. Chromacode Inc., of Carlsbad, Calif., is looking to help change that. The company reported the commercial launch of its first multiplex test using its High Definition Polymerase Chain Reaction (HDPCR) technology. Chromacode said the HDPCR Tick-Borne Pathogen (TBP) panel is the only multiplex PCR test that detects nine of the most common tick-borne pathogens in a single test. This past summer, Quest Diagnostics Inc. helped put that in perspective after looking at more than 6 million de-identified laboratory test results over the past seven years and determining that the disease spiked between 2016 and 2017.

Workplace drug testing was jump-started by President Reagan’s 1986 executive order mandating it for federal employees. In 1988, Congress passed The Drug-Free Workplace Act (41 U.S.C. 81). This law requires some Federal contractors and all Federal grantees to agree that they will provide drug-free workplaces as a precondition of receiving a contract or grant from a Federal agency. Over 9.5 million urine drug tests were positive in the U.S. workforce in 2015. The rates increased to 4% of workers tested in 2015 versus 3.9% the year before, per Quest Diagnostics.

On Dec 5, we issued an updated research report on Quest Diagnostics, Inc.. The stock carries a Zacks Rank #3. Over the past three months, shares of this major commercial laboratory services provider have outperformed its industry. The stock has declined 18% compared with the industry’s 19.9% fall.

he boom of blockchain and distributed ledger technologies have inspired healthcare organizations to test the capabilities of their data. Quest Diagnostics, in partnership with Humana, MultiPlan, and UnitedHealth Group’s Optum and UnitedHealthcare, have launched a pilot program that applies blockchain technology to improve data quality and reduce administrative costs associated with changes to healthcare provider demographic data.

Quest Diagnostics recently announced it will contribute biomarker implementation, population health analytics and a national lab platform as a pillar supporter of One Brave Idea, the research initiative cofounded by the American Heart Association (AHA) and Verily Life Sciences with significant support from AstraZeneca. The company said it hopes to advance the work to identify coronary heart disease at the earliest transition from wellness to disease.

At 5.7 percent Louisiana’s drug test positivity rate is over 1 percent higher than the national average, according to a map produced by Quest Diagnostics' drug testing index.

Quest Diagnostics Inc (NYSE:DGX) institutional sentiment increased to 0.93 in Q2 2018. Its up 0.13, from 0.8 in 2018Q1. The ratio has increased, as 217 funds opened new and increased equity positions, while 234 cut down and sold their stakes in Quest Diagnostics Inc. The funds in our partner’s database reported: 110.90 million shares, down from 111.81 million shares in 2018Q1. Also, the number of funds holding Quest Diagnostics Inc in their top 10 equity positions increased from 0 to 3 for an increase of 3. Sold All: 30 Reduced: 204 Increased: 145 New Position: 72.

Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the American Society of Hematology (ASH) Annual Meeting Dec. 1-4. Their findings provide new insights into the progression of the disease from precursor conditions and suggest approaches for novel treatments. Testing will be performed at each participant's local Quest Diagnostics laboratory. To sign up for the study, please visit http://www.promisestudy.org.

Aetna, a CVS Health business, and Ascension have joined the pilot project applying blockchain technology to improve data quality and reduce administrative costs associated with changes to health care provider demographic data. Humana, MultiPlan, Quest Diagnostics and UnitedHealth Group’s (NYSE: UNH) Optum and UnitedHealthcare announced the launch of the Synaptic Health Alliance pilot project in April.

Quest Diagnostics made it official: It is coming to the city and bringing 1,100 jobs. The company told officials it hopes to break ground for the 250,000-square-foot facility and accompanying five to seven-story parking garage this spring, officials said.